Braftovi (Encorafenib) 75mg Capsules | BRAF Inhibitor | GLT
Tap "Request a Quote" to open WhatsApp — the product details are already filled in. Just add your quantity and destination country.
- We reply within 24 hours with pricing, availability & COA
- Serves individuals and institutions worldwide
Prefer email? [email protected] · +86 15234153837
Generic Information: Braftovi (United States)
Braftovi is the United States brand of encorafenib, an oral BRAF kinase inhibitor developed by Array BioPharma. It is supplied as 75 mg capsules in two pack sizes: 90 capsules and 180 capsules per bottle, matching the large-pack convenience common in the US market. Encorafenib is a selective inhibitor of the BRAF V600E and V600K mutant kinases that drive tumour growth in a subset of melanomas, colorectal cancers and non-small cell lung cancers. As a prescription oncology medicine, Braftovi is used only after a test confirms the tumour carries the relevant BRAF mutation.
What Is Braftovi (Encorafenib) Used For?
Braftovi is indicated for adults whose tumours carry a BRAF V600 mutation. In the United States it is approved, in combination with binimetinib, for unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, and for metastatic non-small cell lung cancer with a BRAF V600E mutation. It is also approved, in combination with cetuximab, for BRAF V600E-mutant metastatic colorectal cancer after prior treatment. Because the medicine only works against mutant BRAF, a genomic test is essential before starting treatment.
How Does Encorafenib Work?
Encorafenib binds and inhibits the mutant BRAF kinase, shutting down the overactive MAPK signalling pathway that fuels the growth of BRAF-mutant cancer cells. By blocking this pathway, the drug slows tumour proliferation and promotes cancer-cell death. Because the mutant protein is the target, encorafenib has little effect on normal, wild-type cells, which is why the companion diagnostic test for BRAF V600E or V600K is a prerequisite. Combining encorafenib with a MEK inhibitor such as binimetinib or with cetuximab deepens the blockade and delays resistance.
Indications
In the United States, Braftovi is approved for three settings. First, with binimetinib, for unresectable or metastatic melanoma carrying a BRAF V600E or V600K mutation. Second, with binimetinib, for metastatic non-small cell lung cancer with a BRAF V600E mutation. Third, with cetuximab, for BRAF V600E-mutant metastatic colorectal cancer in adults who have already received systemic therapy. Encorafenib is not indicated for patients whose tumours are BRAF wild-type, as paradoxically activating the pathway can then stimulate growth.
Dosage
The recommended dose of Braftovi depends on the indication. For melanoma and non-small cell lung cancer it is 450 mg (six 75 mg capsules) once daily with binimetinib; for colorectal cancer it is 300 mg (four 75 mg capsules) once daily with cetuximab. At the 450 mg dose, the 90-capsule bottle covers a 15-day supply and the 180-capsule bottle a 30-day supply. Dose reductions or interruptions may be needed depending on tolerability and side effects, and should always follow the treating oncologist's plan.
Side Effects
The most common adverse reactions to encorafenib include fatigue, nausea, vomiting, abdominal pain, diarrhoea and decreased appetite. Skin reactions such as rash and itching are also frequent, and patients may develop new skin lesions that require monitoring by a dermatologist. Other effects can include joint pain, muscle pain, headache, fever and laboratory changes in liver enzymes or blood counts. New or worsening skin growths, eye problems and unusual bleeding should be reported to the doctor promptly.
Storage
Store Braftovi capsules at room temperature, away from moisture and heat, in the original container with the cap tightly closed. Keep out of the reach of children and do not use beyond the expiry date printed on the bottle. No refrigeration is required.
Why Choose the GLT?
Braftovi in the large 90- and 180-capsule US pack sizes is a cornerstone of BRAF-mutant cancer therapy, but securing genuine, properly documented stock across borders can be difficult. GLT provides a dependable sourcing route for the US-packaged originator product, with verification of authenticity, current availability and the export documentation required for import. Whether you are an institution stocking for a BRAF-mutant patient population or an individual patient with a valid prescription, GLT keeps the procurement process transparent and traceable.
How to Order
To source US Braftovi (encorafenib) through GLT, contact us on WhatsApp at +86 15234153837 or email [email protected]. Tell us the pack size (90 or 180 capsules), the quantity and your destination country, and we will confirm current stock, sourcing origin and the documentation needed for import. A valid prescription and BRAF-mutation test result are required, and we serve both institutions and individual patients.
FAQ
Is Braftovi the same as encorafenib? Yes. Braftovi is the brand name and encorafenib is the generic name of the same BRAF inhibitor developed by Array BioPharma.
Which cancers does Braftovi treat? In the US it is approved for BRAF V600-mutant melanoma, BRAF V600E-mutant metastatic colorectal cancer and BRAF V600E-mutant non-small cell lung cancer, each in specific combinations.
Do I need a BRAF test before taking encorafenib? Yes. Encorafenib only works when the tumour carries a BRAF V600E or V600K mutation, so a confirmed genomic test result is required before treatment.
What is the daily dose of Braftovi? It depends on the indication — 450 mg (six capsules) once daily for melanoma and lung cancer, and 300 mg (four capsules) once daily for colorectal cancer, each with the prescribed partner drug.
Can I buy Braftovi without a prescription? No. Braftovi is a prescription oncology medicine and must be used under the supervision of an oncologist.